Can empagliflozin (Jardiance) be initiated in a patient with severe renal impairment (eGFR 24 mL/min/1.73 m²)?

Empagliflozin (Jardiance) Cannot Be Initiated at eGFR 24 mL/min/1.73 m²

Do not start empagliflozin in a patient with an eGFR of 24 mL/min/1.73 m²; current guidelines and FDA labeling restrict initiation to patients with eGFR ≥20 mL/min/1.73 m² for heart failure or chronic kidney disease indications, but the 2022 ADA/KDIGO consensus explicitly states that empagliflozin initiation is "not recommended" when eGFR is below 45 mL/min/1.73 m² for glycemic control or below 20 mL/min/1.73 m² for heart failure. 1

Guideline-Based Initiation Thresholds

ADA/KDIGO 2022 Consensus Position

• Empagliflozin initiation is not recommended when eGFR is <30 mL/min/1.73 m² for glycemic control or <20 mL/min/1.73 m² for heart failure. 1
• The consensus table explicitly states "Use not recommended with eGFR <45 mL/min/1.73 m²" for empagliflozin across all CKD stages 3b, 4, and 5. 1
• This is the most conservative recommendation among SGLT2 inhibitors; dapagliflozin may be initiated down to eGFR 25 mL/min/1.73 m², but empagliflozin has stricter thresholds. 1

KDIGO 2024 Update vs. Older Guidance

• The KDIGO 2024 guideline gives a Class 1A recommendation for SGLT2 inhibitors when eGFR ≥20 mL/min/1.73 m², but this applies to the class as a whole and specifically to agents with trial data at those levels (primarily dapagliflozin and empagliflozin in EMPA-KIDNEY). 2
• For empagliflozin specifically, KDIGO states that initiation "must not" occur when eGFR is persistently <20 mL/min/1.73 m². 2
• At eGFR 24 mL/min/1.73 m², you fall into a gray zone: above the absolute contraindication threshold of 20 but below the ADA/KDIGO consensus threshold of 30–45 depending on indication. 1, 2

FDA Labeling Constraints

• The FDA label states there are "insufficient data to support a dosing recommendation in patients with eGFR below 20 mL/min/1.73 m²" and that heart failure studies enrolled patients with eGFR ≥20 mL/min/1.73 m². 3
• For glycemic control, FDA guidance discourages use when eGFR is <30 mL/min/1.73 m² in patients without established cardiovascular disease or cardiovascular risk factors. 3
• The label does not explicitly authorize initiation at eGFR 24 for any indication; it only states "no dose adjustment is recommended" for patients already on therapy whose eGFR declines into that range. 3

Why Empagliflozin Is More Restrictive Than Dapagliflozin

• Dapagliflozin has explicit approval and guideline support for initiation at eGFR ≥25 mL/min/1.73 m² for cardiovascular and kidney protection, even when glucose-lowering efficacy is lost. 4
• Empagliflozin's pivotal EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m², but the ADA/KDIGO consensus and FDA labeling have not translated that into a clear initiation recommendation below eGFR 30–45. 1, 5
• The 2022 consensus table shows empagliflozin as "use not recommended" at eGFR <45, whereas dapagliflozin is explicitly endorsed at 10 mg daily down to eGFR 25. 1

Continuation vs. Initiation Distinction

• If a patient is already receiving empagliflozin and their eGFR declines to 24 mL/min/1.73 m², you should continue the drug until dialysis is required, because cardiovascular and renal benefits persist. 2
• However, starting empagliflozin de novo at eGFR 24 is not supported by current consensus guidelines, which reserve initiation for higher eGFR thresholds. 1, 2

Practical Algorithm for SGLT2 Inhibitor Selection at eGFR 24

1. Check the indication:

   • For heart failure or CKD progression risk with eGFR 24, choose dapagliflozin 10 mg daily (Class 1A recommendation, eGFR ≥25). 4
   • For glycemic control alone, no SGLT2 inhibitor should be initiated at eGFR 24 because glucose-lowering efficacy is negligible. 1

2. Assess volume status and diuretic use:

   • Reduce loop or thiazide diuretic dose by 30–50% before starting any SGLT2 inhibitor if the patient is elderly, has low blood pressure, or appears volume-depleted. 4

3. Adjust background glucose-lowering therapy:

   • If glycemic targets are already met, lower insulin dose by ≈20% or decrease sulfonylurea dose to avoid hypoglycemia. 4

4. Monitor for the expected early eGFR dip:

   • An acute decline of 2–5 mL/min/1.73 m² within 2–4 weeks is typical and reflects reversible hemodynamic changes, not kidney injury; do not discontinue therapy. 4, 2

5. Re-measure eGFR and volume status 2–4 weeks after initiation, then every 3–6 months. 4

Common Pitfalls to Avoid

• Do not assume that EMPA-KIDNEY trial data automatically authorize empagliflozin initiation at eGFR 24; the ADA/KDIGO consensus and FDA labeling remain more conservative than the trial enrollment criteria. 1, 5
• Do not withhold dapagliflozin at eGFR 24 if the indication is heart failure or CKD; it is explicitly recommended at this level. 4
• Do not stop an SGLT2 inhibitor solely because of the early eGFR dip; this is expected and not a sign of acute kidney injury. 4, 2
• Do not initiate empagliflozin for glucose lowering at eGFR 24; glycemic efficacy is lost below eGFR 45, and the drug should only be used for cardiovascular or renal protection at lower eGFR levels. 1

Safety Considerations at eGFR 24

• Volume depletion risk is low but monitor for hypotension, especially in patients ≥75 years or on concurrent diuretics. 2, 3
• Genital mycotic infections occur in ≈6% of SGLT2 inhibitor users; provide hygiene counseling at start-up. 4, 2
• Educate patients on "sick-day rules": hold the SGLT2 inhibitor during acute illness (vomiting, diarrhea, prolonged fasting) or before major surgery (withhold ≥3 days) to reduce ketoacidosis risk. 4, 2
• Euglycemic diabetic ketoacidosis can occur even when blood glucose is <250 mg/dL; maintain at least a low-dose insulin regimen in insulin-requiring patients. 2, 3

Bottom Line

At eGFR 24 mL/min/1.73 m², initiate dapagliflozin 10 mg daily (not empagliflozin) if the indication is heart failure or CKD progression risk; empagliflozin initiation is not recommended below eGFR 30–45 per ADA/KDIGO consensus, even though continuation is appropriate if the patient is already on therapy. 1, 4, 2